A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

Phase 2 Completed 41 enrolled Chase Pharmaceuticals Corporation, an affiliate of Allergan plc

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients with Alzheimer's Disease Type Dementia.

Timeline

Start: 2014-07-31
Primary completion: 2016-07-31
Completion: 2016-07-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CPC-201	Unknown	—	—

A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

Summary

Timeline

Drugs

Indications